Matching-adjusted indirect comparison of zanubrutinib and real-world chemotherapy, rituximab and chemoimmunotherapy in relapsed or refractory marginal zone lymphoma. (PubMed, J Comp Eff Res) - Oct 7, 2026 - "Findings were consistent across leave-one-out analyses and when excluding patients who received chemotherapy only. Modeling using clinical trial and real-world data from an unanchored matching-adjusted indirect comparison suggests that zanubrutinib was associated with longer PFS and OS compared with chemotherapy, rituximab or CIT in patients with R/R MZL."
Journal • Real-world evidence • Hematological Disorders • Hematological Malignancies • Lymphoma • Marginal Zone Lymphoma • Non-Hodgkin's Lymphoma • Oncology
|
|
Caitlin Smare; Harriet S Walter; Ina Zhang; Kaijun Wang; Kim M Linton; Leyla Mohseninejad; Renata Walewska; Sam Keeping; Silvy Mardiguian
|